The COVID-19 pandemic highlighted the urgent need for effective therapeutic agents against SARS-CoV-2. Although vaccines ...

SARS-CoV-2 escapes from immune responses by cytotoxic T cells via impaired MHC-I expression which is caused by reducing both the amount and function of NLRC5 (Koichi Kobayashi).

Small-molecule inhibitors targeting viral proteins could serve as an effective alternative for controlling the spread of COVID-19 at both individual and community levels. In this vein, a recent study ...

SARS-CoV-2, the virus responsible for COVID-19 ... and omicron BA.5) , blocking viral entry into pre-treated cells and ...

A newly discovered bat coronavirus uses the same cell-surface protein to gain entry into human cells as the SARS-CoV-2 virus that causes COVID-19, raising the possibility that it could someday spread ...

Back in 2021, at the height of the pandemic, scientists at Pfizer revealed the development of a novel antiviral molecule, ...

HKU5-CoV-2 is found in bats which which was discovered in China and uses the ACE2 receptor for cell entry. It is very similar to SARS-CoV-2 but as per the Wuhan Institute of Virology, HKU5-CoV-2 ...

Scientists found that it can bind to human ACE2 receptors, similar to SARS-CoV-2 (the virus behind COVID-19). This suggests it has the potential for animal-to-human transmission. Experts note that ...

(A) A comprehensive analysis of caffeine binding to one of the spike proteins; (B, C) Caffeine interacts with critical amino acids in the SARS-CoV-2 S ... with viral entry mechanisms, thereby ...